Maryland Team Wins First Phase of NEI Contest to Create Human Retina

October 6, 2017: By Jon Swedien
Erin Lavik, ScD

Erin Lavik, ScD

A team from the University of Maryland, Baltimore County, beat out 12 other entries to win the first phase of a National Eye Institute (NEI) contest to create a living model of the human retina.

The NEI, part of the National Institutes of Health, announced the winner Sept. 28. The honor included a prize of $90 thousand.

The NEI’s 3-D Retina Organoid Challenge (3-D ROC) initiative seeks to design human retinas from stem cells. The submissions were evaluated based on their innovativeness and feasibility, the NEI said.

The winning concept was a proposal to build a retina by screen printing adult neural progenitor-derived retinal neurons in layers that mimic the structure of the human retina. The system is designed to be scalable, efficient, and reproducible, enabling high-throughput screening for drug testing, the NEI said. Erin Lavik, ScD, led the winning team.

The NEI plans to launch a second phase of the content this fall and to award a combined total of $1 million to teams that demonstrate the functionality of a retina organoid prototype. Further details on the challenge will be provided in an official announcement, NEI said.

NEI also awarded five teams with an honorable mention. They were led by:

–Rebecca Carrier, PhD, Northeastern University, Boston;

–David Gamm, MD, PhD, University of Wisconsin, Madison;

–Wei Liu, PhD, Albert Einstein College of Medicine, Bronx, New York;

–Daniel Pelaez, PhD, University of Miami, Florida;

–Katja Schenke-Layland, PhD, Fraunhofer Institute for Interfacial Engineering and Biotechnology, Stuttgart, Germany.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Offers Compounded Alternative to Restasis for Dry Eye

US District Court Invalidates Four Restasis Patents

BioTime Prices $25 Million Public Offering of Common Stock

Gemini Completes $42.5 Million Series A Financing for Dry AMD Treatment

BIOPHYTIS Raises €10.4 Million to Develop Anti-Aging Drugs, One for Dry AMD

Amydis Receives $530 Thousand NIH Award to Advance Ophthalmic Diagnostic Probes

Realm Announces Completion of $26 million Private Placement

Sight Sciences Secures $10 Million in Oversubscribed Series C Financing

Aerpio Names Stephen Hoffman CEO; Founder Joseph Gardner Remains President

FDA Advisory Panel Recommends Aerie’s Rhopressa for Glaucoma Patients

FDA Panel Unanimously Backs Spark’s Luxturna as Retinal Gene Therapy

PanOptica Secures $11 Million to Advance Topical Anti-VEGF Eye Drop for Neovascular AMD

Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

Shire Sues Allergan, Claiming Bundling Tactics Block Restasis Competitors

Allergan Decries ‘Unfair’ Patent Challenge Process as US House Launches Probe of Tribe Deal

Coming soon

2017 Refractive Surgery Report: A Global Market Analysis for 2016 to 2022